



Endotyping Non-IgE-mediated Immunoreactivity to Polyethylene Glycol: Implications for Allergic Patients

Celso Eduardo Olivier ^{a*}, Daiana Guedes Pinto ^a,
Ana Paula Monezzi Teixeira ^a,
Jhéssica Letícia Santos Santana ^a,
Raquel Acácia Pereira Gonçalves Santos ^a
and Regiane Patussi Santos Lima ^b

^a Instituto Alergoimuno de Americana, Brazil.

^b Lavoisier's Laboratories, São Paulo, Brazil.

Authors' contributions

This work was carried out in collaboration among all authors. Author CEO designed the study, wrote the protocol and the manuscript's first draft, and managed the literature searches. Authors DGP, APMT, JLSS and RPSL performed laboratory research. Author RAPGS performed cutaneous tests. All authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.9734/aji/2024/v7i1135>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here:

<https://www.sdiarticle5.com/review-history/119914>

Original Research Article

Received: 01/07/2024

Accepted: 16/07/2024

Published: 17/07/2024

*Corresponding author: E-mail: celso@alergoimuno.med.br;

Cite as: Olivier, Celso Eduardo, Daiana Guedes Pinto, Ana Paula Monezzi Teixeira, Jhéssica Letícia Santos Santana, Raquel Acácia Pereira Gonçalves Santos, and Regiane Patussi Santos Lima. 2024. "Endotyping Non-IgE-Mediated Immunoreactivity to Polyethylene Glycol: Implications for Allergic Patients". *Asian Journal of Immunology* 7 (1):100-111. <https://journalaji.com/index.php/AJI/article/view/135>.

ABSTRACT

Background: Several publications report polyethylene glycols (PEGs) and PEGylated therapeutics as responsible for non-IgE-mediated allergic reactions. There is no standardized lab exam that can endotype (quantify the participation of these mechanisms inside each patient's pattern of symptoms) besides *in vivo* provocation tests.

Objective and Aim: To evaluate the Tube Titration of Precipitins (TTP) and the Leukocyte Adherence Inhibition Test (LAIT) to discriminate and endotype non-IgE-mediated immunoreactivity against a PEGs solution in patients with non-IgE-mediated allergic phenotypes.

Research Design and Research Protocol: To retrospectively examine the medical charts of two cohorts (with 100 patients each) diagnosed with non-IgE-mediated allergic rhinitis, allergic bronchitis, asthma, allergic sinus headache, atopic dermatitis, and/or urticaria who were investigated with the help of TTP or *ex vivo* challenge tests monitored by LAIT against PEGs.

Methodology: We identified the registered results of the semi-quantitative serum TTP against 1 mg/mL PEGs 4000 solution, which were distributed in ranges through a cascade distribution chart to outline the variability of the results inside the first cohort. The LAI done with the *ex vivo* challenges with 1 mg/mL PEGs 4000 solution were distributed in ranges through a cascade distribution chart. The statistical characteristics of the two cohorts were calculated.

Results: The TTP showed a wide distribution range of results. The mean was estimated at 1:246; the median at 1:192; the standard deviation at 1:188. The LAIT showed a wide distribution range of results. The LAI ranged from 0% to 98%. The mean was 41.9%; the median was 45%; the standard deviation was 28.5%. The cascade distribution demonstrates a wide range of LAI results.

Conclusion: Some patients showed any or low immunoreactivity during the *ex vivo* challenge test, while most displayed moderate or strong immunoreactivity, which could reflect the participation of PEGs antibodies in a non-IgE-mediated hypersensitivity condition.

Keywords: Allergy; asthma; atopic dermatitis; bronchitis; COVID-19 vaccination; diagnosis; exposome-wide association study; endotype; hypersensitivity; leukocyte adherence inhibition test; macrogol; Non-IgE-mediated immunoreactivity; precision medicine; polyethylene glycol; E1521; rhinitis; sinus headache; urticaria.

ABBREVIATIONS

LAI : Leukocyte Adherence Inhibition
LAIT : Leukocyte Adherence Inhibition Test
TTP : Tube Titration of Precipitins
PEGs : Polyethylene Glycol Polymers

1. INTRODUCTION

For a long time, petroleum-derived polymeric products were discarded as tars. The first polymerized structures to be identified from tars were the polyethylene glycol polymers (PEGs) after continued condensation studies in 1860 [1]. PEGs are polymers of parental ether monomers such as ethylene glycol, ethylene oxide, or oxyethylene, commonly available as compounds together with their anionic or nonionic derivatives, in mixtures of different chain lengths polymers, indicated by their average molecular weight (200 to over 10,000 Da) [2].

PEGs are used as solvents and emulsifying agents in processed food, cosmetics, medicines, cleansing, and personal care products. They

may also be involved in the production of fabrics, plastics, resins, papers, ceramics, glasses, rubber, metals, wood preservatives, et cetera [3].

“Chemically designated as alpha-hydro-omega-hydroxypoly(oxy-1,2-ethanediol) or polyethylene oxides, PEGs are regulated additives, allowed to be used as emulsifiers in industrialized food and food supplements (E 1521) and as plasticizers in film coating formulations for food supplement tablets and capsules” [4]. “PEGs are amphipathic substances soluble in water and in many organic solvents, including aliphatic ketones, alcohols, chloroform, glycol ethers, esters, and aromatic hydrocarbons. Acting as emulsifiers, they prevent the separation of unstable water/oil emulsions in industrialized food such as mayonnaise, dairy-based ice cream, frozen yogurts, margarine, blended spreads, cakes, pastries, and frozen desserts” [5]. When used as dietary emulsifiers, PEGs may increase intestinal permeability by interfering with the physical properties of the mucus layer, facilitating the growth of pro-inflammatory intestinal microbiota and

contributing to the impairment of inflammatory intestinal diseases and food allergies [6,7].

PEGs (also designated as macrogol in pharmacy) are used as vehicles for drugs and ointment bases, capsules, tablet and pill binders, suppositories, and liquid prescriptions, including parenteral, topical, ophthalmic, oral, and rectal preparations. They also prevent protein aggregation and inactivation of pharmaceutical proteins encapsulated in bioerodible polyester microspheres, acting as stabilizers [8]. PEGylation (or pegylation) is a process developed in the 1970s to covalently or non-covalently attach PEG polymers to molecules, such as drugs, therapeutic proteins, peptides, antibody fragments, and vesicles, then described as "PEGylated" [9]. "PEGylation changes the physical and chemical properties of the biomedical molecule, such as its conformation, electrostatic binding, and hydrophobicity, resulting in an improvement of the pharmacokinetic behavior of the drug, reducing coalescence, degradation and *in vivo* elimination of the active pharmacological principles" [10-12]. "PEGylated products can induce anti-PEG antibody production associated with type III complement-activated immunoreactivity" [13].

"Lower molecular weight PEGs are absorbed by the digestive tract and excreted in the urine; however, high molecular weight PEGs are not absorbed and form hydrogen bonds with water in the gastrointestinal tract, where they hydrate stools" [14]. Long-chain PEGs are laxative medications in isosmotic balanced electrolyte preparations [15]. PEGs are also used in topical dermatological preparations as penetration enhancers [16]. PEGs and their derivatives (laureth, ceteth, cetareth, steareth, oleth, laurate, dilaurate, stearate, distearate) do not readily penetrate intact skin and are added to a great variety of cosmetic applications as surfactants, cleansing agents, emulsifiers, skin conditioners, and humectants [17]. However, absorption through damaged skin of PEGs present in burn creams was associated with fatal intoxication in burned patients characterized by acute renal failure and metabolic acidosis with increased calcium, anion, and osmolar gap [18]. Allergic reactions due to PEGs used as excipients have already been reported [19].

Pharmaceutical excipients are a hidden potential cause of drug and vaccine hypersensitivity reactions [20]. Allergic reactions to PEGs were put into evidence, particularly after Pfizer-

BioNTech® and Moderna® mRNA COVID-19 vaccines were approved for mass vaccination [21,22].

Endotyping pharmaceutical excipient immunoreactivity has become a herculean task due to the variety and diversity of formulations, mainly after the appearance of the PEGylated lipid nanoparticle vaccines [23]. PEGs are the most popular nanomedicine components due to their chemical properties [24].

The IgE-mediated anaphylaxis elicited by PEGs excipients was the first and easiest endotype to diagnose [25,26]. Skin and basophil activation tests are the most available assays to identify immediate and/or IgE-mediated allergy to PEGs [27]. However, intradermal skin tests performed with PEGs may produce immediate anaphylactic reactions, which makes the percutaneous route a more secure way to perform *in vivo* challenges [28]. At our facilities, we had performed hundreds of skin tests with PEGs employing the skin scrape test technique with no systemic reaction, despite dozens of positive wheal-and-flare local diagnostic reactions elicited by PEGs [29]. A Dual Cytometric Bead Assay (DCBA) was recently described for detecting anti-PEG IgG, IgM, and IgE in patient sera [30].

Besides the type I IgE-mediated hypersensitivity reaction, several other mechanisms have been proposed, such as IgG-mediated anaphylaxis (Complement-related or not) and direct mast cell activation [31]. The production of Anti-Poly (Ethylene Glycol) antibodies, besides provoking hypersensitivity reactions, can also be problematic when a PEGylated drug is administered, accelerating drug clearance and decreasing its therapeutic efficacy [32,33]. COVID-19 mRNA vaccination is associated with elevated levels of vaccine-induced anti-PEGs antibodies and increased systemic reactogenicity [34]. PEGs excipients are also suspected to elicit life-threatening immune-induced organ-specific reactions such as acute pancreatitis, acute interstitial nephritis, and liver injury [35].

We routinely employ the Leukocyte Adherence Inhibition Test (LAIT) and the Tube Titration of Precipitins (TTP) in our facilities as a triage to evaluate non-IgE-mediated immunoreactivity against suspected allergens before the performance of more exhaustive *in vivo* provocation tests [36-42]. The present study hypothesizes that the LAIT and the TTP may

differentiate diverse endotypes and degrees of immunoreactivity against PEGs among patients suffering from the most common allergic phenotypes. To demonstrate diversity in immune responses and to evaluate the potential of the LAIT and the research of precipitins to endotyping non-IgE-mediated immunoreactivity against PEGs, we retrospectively compiled the electronic medical charts of patients with non-IgE-mediated allergic rhinitis, allergic bronchitis, asthma, sinus headache, atopic dermatitis, and/or urticaria who were investigated with these procedures into our institution.

2. MATERIALS AND METHODS

2.1 Subjects

After receiving Institutional Review Board approval from the Instituto Alergoimuno de Americana (Brazil; 05/2024), we reviewed the electronic chart of 9.000 outpatients who attended our facility from January 2018 to June 2024.

The sample selection was performed by retrieving the results from the electronic sheets.

A cohort of 100 outside patients had been submitted to TTP with PEGs solution 1mg/mL for presenting non-IgE-mediated allergic rhinitis, allergic bronchitis, asthma, allergic sinus headache, atopic dermatitis, and/or urticaria. This cohort counted 31 males; mean age 34.8 years; standard deviation (SD) 21.3 years; range 0 to 80 years; median 32.5 years; mode = 28 years (appeared five times).

A different cohort of 100 outside patients had been submitted to an *ex vivo* allergen challenge test with PEGs solution 1mg/mL monitored with LAIT for presenting non-IgE-mediated allergic rhinitis, allergic bronchitis, asthma, allergic sinus headache, atopic dermatitis, and/or urticaria. This cohort counted 27 males; mean age 39.9 years; SD 20.5 years; range 3 to 84 years; median 39.5 years; modes = 24 and 41 years (each appeared four times).

This study did not include patients under biological and/or systemic anti-inflammatory therapy. These procedures were offered to patients with clinical suspicion of PEGs' hypersensitivity who demonstrated a non-reactive or inconclusive allergic skin scrape test against PEGs' solution [29].

2.2 PEGs Solution

The PEGs solution was prepared with powdered PEG 4000 (acquired from ACS Científica) diluted with isotonic saline solution at 1 mg/mL to perform the allergic skin scrape tests, TTP, and LAIT.

2.3 *Ex vivo* Investigation: Leukocyte Adherence Inhibition Test

2.3.1 Procedure for allergen *ex vivo* challenging

We performed the LAIT as previously described [43-51]. Shortly, each donor's fresh plasma was divided into two parts and used in paralleled *ex vivo* challenging tests with PEGs solution 1 mg/mL and the unchallenged plasma assay. We collected the plasma with high leukocyte content (buffy coat) from the heparinized tube after one hour of sedimentation at 37°C. Then we distributed aliquots of 100 μ L into Eppendorf tubes kept under agitation for 30 minutes (200 rpm at 37°C) with PEGs solution (10 μ L of a solution with 1mg/mL and pH 7.5) or without PEGs solution (when used as control).

2.3.2 Procedure for Adherence Assay

After incubation, the plasma was allocated into a standard Neubauer hemocytometer counting chamber with a plain, non-metallic glass surface and left to stand for 2 hours at 37 °C in the humidified atmosphere of the covered water bath to allow leukocytes to adhere to the glass. Next, we counted the leukocytes, removed the coverslip, and washed the chamber by immersion in a beaker with PBS at 37°C. Then, we added a drop of PBS to the hemocytometer's chamber and allocated a clean coverslip over it. The remaining cells were counted in the same squares as previously examined.

2.3.3 Procedure for calculating the adherence inhibition

The percentage of Leukocyte Adherence (LA) of each assay was estimated as: (the number of leukocytes observed on the hemocytometry chamber after washing divided by the number of leukocytes observed on the hemocytometry chamber before washing) and multiplied by 100 (%). The Leukocyte Adherence Ratio (LAR) was estimated based on the ratio between the LA from the antigen-specific challenged plasma and the LA from the unchallenged control plasma:

LAR = LA of the challenged sample divided by LA of unchallenged control plasma multiplied by 100 (%). To further calculate the Leukocyte Adherence Inhibition (LAI), we subtracted the LAR from 100 (%). We employed the LAI results for the cascade distribution chart and the statistics calculations, both performed with the help of the Microsoft Excel® statistical package.

2.4 In vitro Investigation: Tube Titration of Precipitins (TTP)

As previously reported, the semi-quantitative TTP against the PEGs solution was performed in a transparent vitreous tube [52]. Shortly, the patient’s blood was collected in a clot-activator collecting tube. After separation, the serum was centrifugated at 2,000 rpm for 10 minutes. The allergen extracts were allocated in sets of eleven glass tubes at progressive duplicated serum dilutions. The progressive dilutions were combined with the 15 µL of the antigen (PEGs solution 1 mg/mL) with 250 µL of the patient’s serum, progressively diluted into physiological saline solution (NaCl 0,9%) in the dilution ratios of 1:1; 1:2; 1:4; 1:8; 1:16; 1:32; 1:64; 1:128; 1:256; and 1:512. One tube was a blank control done with the water and serum to observe occasional spontaneous precipitation (Sia Test). After 24 hours, one of us examined the tubes, and the titers (the highest dilution factor that yields a positive visual reading) were recorded [53].

3. RESULTS

As a retrospective survey, there was no research protocol; therefore, we report the incidental immune investigation as registered in the digital medical charts.

The TTP showed a wide distribution range of results. There were two negative results. Most positive results concentrated on the higher dilutions (Fig. 1). The mean was estimated at 1:246; the median was 1:192; the SD was estimated at 1:188; the mode was 1:512 (appeared 30 times). All Sia tests were negative.

The LAIT showed a wide distribution range of results. The LAI ranged from 0% to 98%. The mean was 41.9%; the median was 45%; the SD was 28.5%; the mode was 0% (appeared seven times). The cascade distribution demonstrates a wide range of distribution of LAI results (Fig. 2). Six patients ignored the presence of the allergen on the plasma and presented no inhibition of leukocyte adherence (LAI = 0%) after contact with the PEGs extract (6% of the tests). Some patients showed any or low immunoreactivity during the *ex vivo* challenge test, while most displayed moderate or strong immunoreactivity, which could reflect the participation of PEGs antibodies in a non-IgE-mediated hypersensitivity condition.




Fig. 1. Cascade distribution chart of the Tube Titration of Precipitins (TTP on the x-axis %) resulting from the PEGs solution against the serially diluted serum of a cohort of 100 tests/subjects (y-axis)




Fig. 2. Cascade distribution chart of the range groups of Leukocyte Adherence Inhibition (LAI) results (x-axis %) of *ex vivo* PEGs solution monitored by the Leukocyte Adherence Inhibition Test (LAIT), according to the respective number of outcomes over a cohort with 100 tests/subjects (y-axis)

4. DISCUSSION

More and more patients are being diagnosed with PEG allergy as an increasing number of processed foods, cosmetics, household products, vaccines, and medicines add PEG to their composition [54]. The development of new PEGylated compounds is advancing, especially among biological immune therapeutics [55]. PEGs are the polymer of choice for the delivery of small drugs, proteins, oligonucleotides, and liposomes due to their biocompatibility and ability to improve pharmacokinetics; however, PEGs are a mixture of different polymers that can stimulate unwanted immunogenic reactions, leading to efforts to develop synthetic (monodisperse) more uniform PEGs [56].

PEG hypersensitivity is associated with medicine-induced anaphylaxis, and PEGylated-drug reactions should prompt PEGs hypersensitivity investigations, especially by use of skin allergic tests with high molecular weight PEGs [57]. Diagnosing PEG allergy is challenging since the traditional allergy testing approaches are insufficient to demonstrate all kinds of hypersensitivity reactions [58]. Besides the IgE-mediated hypersensitivity reaction, the production of specific IgM and IgG antibodies and Complement activation were also described

[59]. Since a methodology for specific-IgE research has not yet been described, the feasibility of *in vitro* challenge tests, such as the Basophil Activation Test, is being studied [60]. Brand new allergic diagnostic techniques (such as performing tests with the help of PEGylated liposomes) are currently being designed to endotype PEGs allergies [61].

The precise diagnosis of the phenotypes and endotypes of hypersensitivities to PEGylated medications is paramount for prescribing a successful PEGs desensitization [62].

This retrospective compilation of our data showed a large distribution of results when we ascertained the results of TTP and TIAL to explore humoral and cellular immunoreactivity against PEGs. These immunoassays do not identify the exact mechanisms responsible for the clinical condition. Instead, they provide clues about sensitization and immunoreactivity distributed into an extensive spectral range between immune tolerance and symptomatic hypersensitivity.

The semi-quantitative study of the serological reactions through the titration of precipitins was the most basic laboratory exam upon which the fundamentals of Immunology were constructed [63]. Precipitating antibodies are classically

associated with a robust immune humoral response against an antigen or allergen [64]. The LAIT is an *ex vivo* challenge test performed with a viable leukocyte buffy coat that can theoretically explore most known immune pathways as it allows the interaction of all immune-circulating participants with the allergen [65]. Similarly, with the TTP, the LAIT did not indicate which pathways are involved in producing the immune cellular response demonstrated by the leukocyte adherence inhibition [66-69].

TTP and LAIT must be interpreted as humoral and cellular markers of the immune response after contact with a specific antigen, configuring themselves as techniques to endotype the exposome phenomenon, as proposed by the exposome-wide association study [70]. TTP and LAIT are complementary triage tests used at our facilities to select worthwhile antigens to proceed with more laborious *in vivo* provocation tests when the specific IgE is undetectable. None of our patients presented an exclusive reaction to PEGs. Every patient was simultaneously tested with several chemical and biological allergens, demonstrating positive results for some of them. Our clinical experience suggests that reactive allergic patients may impair their symptoms by an additional immunoreactivity against PEGs.

This preliminary retrospective survey demonstrated an extensive range of results from the TTP and the *ex vivo* challenge test monitored by LAIT against PEGs in two cohorts of patients with various allergic symptoms. The preliminary results support that the TTP and LAIT performed with 1 mg/mL PEGs 4000 solution may discriminate diverse degrees of *in vitro* and *ex vivo* immunoreactivity in patients suffering from diversified allergic phenotypes. It is worth carrying out more in-depth studies to evaluate the usefulness of TTP and LAIT in endotyping non-IgE-mediated hypersensitivity to PEGs.

5. CONCLUSION

Our society is now flooded with chemical derivatives through industrialized foods, cosmetics, cleansing products, and medicines producing unknown immunoreactivity [71]. Our preliminary results show that the LAIT and TTP may differentiate diverse degrees of immunoreactivity against PEGs in patients clinically diagnosed with non-IgE-mediated

allergies. This methodology can provide a socioeconomic impact since the technology to perform TIAL and TTP is inexpensive and can be achieved in a single lab room attached to the clinical facility with minimum laboratory equipment. However, the propaedeutic meaning of these results and the possibility of interferences must be better established [72]. Studies designed to establish diagnostic cutoffs focused on the quality-by-design approach with prospective larger double-blind cohorts need to evaluate the potential contribution of LAIT and TTP for endotyping immunoreactivity in patients suspected of symptomatic hypersensitivity against PEGs [73,74].

6. LIMITATIONS

This study is a retrospective analysis of data collected over six years. There was no protocol research, and the subject's data were limited to the essentials available on our electronic sheets. Therefore, we could not establish a cross-comparison between positive and negative controls to validate the results. The number of subjects is appropriate for a preliminary study; however, future studies must be more comprehensive and include patients' follow-up information. The lack of a research protocol implies the possibility of a bias produced by the physician's point of view, which indicated the exam (CEO) based on a clinical suspicion led by the anamnesis, physical examination, and *in vivo* provocation tests. The study lost many of these patients to follow-up, so assuring the relationship between the immunoassays' results and the patient's clinical outcome is impossible.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Authors hereby declare that no generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during the writing or editing of manuscripts.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The authors have collected and preserved written ethical approval per international standards.

ACKNOWLEDGEMENTS

The Instituto Alergoimuno de Americana funded this work. We want to thank our new laboratory technician, Alessandra Vieira de Oliveira, for participating in the exams.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ravve A. Principles of polymer chemistry - Third edition. Springer, New York. 2012;1.
2. Jang HJ, Shin CY, Kim KB. Safety Evaluation of polyethylene glycol (PEG) compounds for cosmetic use. *Toxicol Res.* 2015;31(2):105-36.
3. Expert Committee on Food Additives. Evaluation of certain food additives. Twenty-third Report of the Joint FAO/WHO In World Health Organization technical report series. Geneve. 1980; 648:17-18.
4. Younes M, Aggett P, Aguilar F, Crebelli R, Dusemund B, Filipič M, et al. Refined exposure assessment of polyethylene glycol (E 1521) from its use as a food additive. *EFSA Journal.* European Food Safety Authority. 2018;16(6):e05293.
5. Cox S, Sandall A, Smith L, Rossi M, Whelan K. Food additive emulsifiers: A review of their role in foods, legislation and classifications, presence in food supply, dietary exposure, and safety assessment. *Nutr Rev.* 2021;79(6):726-741.
6. Bancil AS, Sandall AM, Rossi M, Chassaing B, Lindsay JO, Whelan K. Food additive emulsifiers and their impact on gut microbiome, permeability, and inflammation: Mechanistic insights in inflammatory bowel disease. *Journal of Crohn's & Colitis.* 2021;15(6):1068-1079.
7. Olivier CE. Considering intestinal permeability and immune metabolism in the treatment of food allergies. *Eur J Clin Med.* 2022;3(3):13-18.
8. Castellanos IJ, Crespo R, Griebenow K. Poly(ethylene glycol) as stabilizer and emulsifying agent: A novel stabilization approach preventing aggregation and inactivation of proteins upon encapsulation in bioerodible polyester microspheres. *J Controlled Release.* 2003;88(1):135-45.
9. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. *Nanomedicine (London, England).* 2011; 6(4):715-28.
10. Veronese FM, Mero A. The impact of PEGylation on biological therapies. *BioDrugs.* 2008;22(5):315-29.
11. Tenchov R, Sasso JM, Zhou QA. PEGylated lipid nanoparticle formulations: Immunological safety and efficiency perspective. *Bioconjugate Chemistry.* 2023;34(6):941-960.
12. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. *FEBS Lett.* 1990;268(1):235-7.
13. Ibrahim M, Ramadan E, Elsadek NE, Emam SE, Shimizu T, Ando H, et al. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. *J Controlled Release.* 2022;351:215-230.
14. Koppen IJN, Broekaert IJ, Wilschanski M, Papadopoulou A, Ribes-Koninckx C, Thapar N, et al. Role of polyethylene glycol in the treatment of functional constipation in children. *J Ped Gastroenterol Nutr.* 2017;65(4):361-363.
15. Corazziari E, Badiali D, Bazzocchi G, Bassotti G, Roselli P, Mastropaolo G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. *Gut.* 2000; 46(4):522-6.
16. Expert Panel Cosmetic Ingredient Review. PEGs. https://www.cir-safety.org/sites/default/files/115_final_peg_s.pdf (accessed April 06, 2024).
17. Fruijtjer-Pöllöth C. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. *Toxicol.* 2005;214(1-2):1-38.
18. Bruns DE, Herold DA, Rodeheaver GT, Edlich RF. Polyethylene glycol intoxication in burn patients. *Burns Incl Therm Inj.* 1982;9(1):49-52.
19. Inoue H, Yoshikawa H, Haraura H, Eguchi T, Kawano Y. Polyethylene glycol allergy

- caused by a diazepam suppository. *Pediatr Int.* 2023;65(1):e15402.
20. Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone-Jr CA. Hidden dangers: Recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. *J Allergy Clin Immunol Pract.* 2021;9(8):2968-2982.
 21. Habran M, Vandebotermiet M, Schrijvers R. Polyethylene glycol allergy and immediate-type hypersensitivity reaction to COVID-19 vaccination: Case report. *J Investig Allergol Clin Immunol.* 2022;32(3):234-235.
 22. Cabanillas B, Akdis CA, Novak N. Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol? *Allergy.* 2021;76(6):1617-1618.
 23. Ieven T, Coorevits L, Vandebotermiet M, Tuyls S, Vanneste H, Santy L, et al. Endotyping of IgE-mediated polyethylene glycol and/or polysorbate 80 allergy. *J Allergy Clin Immunol Pract.* 2023;11(10):3146-3160.
 24. Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA. To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives. *Advanced drug delivery reviews.* 2022;180:114079.
 25. Giavina-Bianchi P, Kalil J. Polyethylene glycol is a cause of IgE-Mediated anaphylaxis. *J Allergy Clin Immunol Pract.* 2019;7(6):1874-1875.
 26. Kelso JM. IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines. *Clin Exp Allergy.* 2022;52(1):10-11.
 27. Brockow K, Mathes S, Fischer J, Volc S, Darsow U, Eberlein B. et al. Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis. *Allergy.* 2022;77(7):2200-2210.
 28. Chiang V, Kan A, Yeung H, Au E, Lau CS, Li PH. Polyethylene glycol allergy: Risks of skin testing and complement-mediated anaphylaxis. *J Investig Allergol Clin Immunol.* 2023;33(1):71-73.
 29. Olivier CE, Argentão DGP, Santos RAPG, Silva MD, Lima RPS, Zollner RL. Skin scrape test: an inexpensive and painless skin test for recognition of immediate hypersensitivity in children and adults. *The Open Allergy Journal.* 2013;6:9-17.
 30. Zhou ZH, Stone-Jr CA, Jakubovic B, Phillips EJ, Sussman G, Park J, et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. *J Allergy Clin Immunol Pract.* 2021;9(4):1731-1733.e3.
 31. Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation. *Allergy.* 2021;76(11):3307-3313.
 32. Freire-Haddad H, Burke JA, Scott EA, Ameer GA. Clinical relevance of pre-existing and treatment-induced anti-poly (Ethylene Glycol) antibodies. *Regener Engineer Transl Med.* 2022; 8(1):32-42.
 33. Gaballa SA, Shimizu T, Takata H, Ando H, Ibrahim M, Emam SE, et al. Impact of Anti-PEG IgM induced via the topical application of a cosmetic product containing PEG derivatives on the antitumor effects of pegylated liposomal antitumor drug formulations in mice. *Mol Pharm.* 2024; 21(2):622-632.
 34. Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. *ACS Nano.* 2022;16(8):11769-11780.
 35. Rogozina O, Ruiz-Fernández C, Martín-López S, Akatbach-Bousaid I, González-Muñoz M, Ramírez E. Organ-specific immune-mediated reactions to polyethylene glycol and polysorbate excipients: three case reports. *Front Pharmacol.* 2023;14:1293294.
 36. Kuratsuji T. Studies on leukocyte adherence inhibition test. Part II. Clinical applications of LAI test to detect delayed type hypersensitivity in infants and children. *Keio J Med.* 1981;30(2):65-9.
 37. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Evaluating non-IgE-mediated allergens' immunoreactivity in patients with "intrinsic" persistent rhinitis with help of the leukocyte adherence inhibition test. *Eur J Med Health Sci.* 2023;5(1):17-22.
 38. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS,

- et al. Evaluating non-IgE-mediated allergens' immunoreactivity in patients formerly classified as "intrinsic" asthmatics with help of the leukocyte adherence inhibition Test. Eur J Clin Med. 2023; 4(2):1-7.
39. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Contribution of the leukocyte adherence inhibition test to the diagnosis of innate Non-IgE-mediated Immunoreactivity against *Alternaria alternata*. Asian J Immunol 2023;6(1):243-251.
 40. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the leukocyte adherence inhibition test to the diagnosis of innate non-IgE-mediated immunoreactivity against *saccharomyces cerevisiae*. Asian J Immunol. 2023;6(1):234-241.
 41. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Contribution of the leukocyte adherence inhibition test to the diagnosis of non-IgE-mediated Immunoreactivity against *Candida albicans* in Patients with Atopic Dermatitis. Asian J Immunol. 2023;6(1):268-276.
 42. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Contribution of the leukocyte adherence inhibition test in diagnosing non-IgE-mediated immunoreactivity against *Aspergillus fumigatus* in patients with allergic rhinitis and asthma. Asian J Immunol. 2024;7(1):12-20.
 43. Olivier CE, Lima RPS, Pinto DG, Santos RAPG, Silva GKM, Lorena SLS, et al. In search of a tolerance-induction strategy for cow's milk allergies: significant reduction of beta-lactoglobulin allergenicity via transglutaminase/cysteine polymerization. Clinics. 2012;67(10):1171-1179.
 44. Olivier CE, Santos RAPG, Lima RPS, Argento DGP, Silva GKM, Silva MD. A novel utility for an old method: The leukocyte adherence inhibition test Is an easy way to detect the immunoreactive interference of the collection tube anticoagulant on cellular immunoassays. Journal of Cell Adhesion; 2014; Article ID 860427 (<http://dx.doi.org/10.1155/2014/860427>):1-6.
 45. Olivier CE, Pinto DG, Lima RPS, Silva MD, Santos RAPG, Teixeira APM, et al. Assessment of immunoreactivity against therapeutic options employing the leukocyte adherence inhibition test as a tool for precision medicine. Eur J Clin Med. 2021;2(3):40-45.
 46. Olivier CE, Pinto DG, Santos RAPG, Lima RPS. Dextran's interference over the leukocyte adherence inhibition test. Academia Letter. 2021; article number 3792.
 47. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Immunoreactivity against dermatophagoides pteronyssinus assessed by the leukocyte adherence inhibition test in patients with intrinsic atopic dermatitis and correlated "Intrinsic" Non-IgE-mediated allergic conditions. Eur J Clin Med. 2021;2(6):45-50.
 48. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the leukocyte adherence inhibition test to the evaluation of cellular immunoreactivity against latex extracts for Non-IgE-Mediated Latex-Fruit-Pollen syndrome in allergic candidates to exclusion diets and allergic desensitization. Eur J Clin Med. 2022; 3(1):11-17.
 49. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the leukocyte adherence inhibition test for the evaluation of immunoreactivity against gluten extracts in non-IgE-mediated / non-autoimmune Gluten-Related Disorders. Eur J Clin Med. 2022;3(2):1-7.
 50. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Leukocyte adherence inhibition test to the assessment of immunoreactivity against cow's milk proteins in Non-IgE-mediated gastrointestinal food allergy. Eur J Clin Med. 2022;3(2):38-43.
 51. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the leukocyte adherence inhibition test to the diagnosis of immunoreactivity against cobalt. Asian J Immunol. 2023;6(1):174-184.
 52. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Intrinsic atopic dermatitis: Titration of precipitins in the screening of food allergens for prescription of elimination diets and desensitization strategies. Eur J Clin Med. 2021.2(6):1-9.

53. Williams CA, Chase MW. CHAPTER 13 - Precipitation reactions. In reactions of antibodies with soluble antigens, Academic Press. 1971;3:1-102.
54. Bruusgaard-Mouritsen MA, Johansen JD, Garvey LH. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. *Clin Exp Allergy*. 2021;51(3):463-470.
55. Hicks ED, Hall G, Hershfield MS, Tarrant TK, Bali P, Sleasman JW, et al. Treatment with elapegedemase restores immunity in infants with adenosine deaminase deficient severe combined immunodeficiency. *J Clin Immunol*. 2024; 44(5):107.
56. Bento C, Katz M, Santos MMM, Afonso CAM. Striving for uniformity: A review on advances and challenges To achieve uniform polyethylene glycol. *Org Process Res Develop*. 2024;28(4):860-890.
57. Kayode OS, Nakonechna A, Siew LQC, Dziadzio M, Kennard L, Rutkowski K, et al. Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study. *Ann Allergy Asthma Immunol*. Published online March 30, 2024. DOI: 10.1016/j.anai.2024.03.022.
58. Perkins G, Troelnikov A, Hissaria P. Reply. *J Allergy Clin Immunol*. 2021; 148(3):902-903.
59. Lisiecka MZ. Polyethylene glycol and immunology: Aspects of allergic reactions and their mechanisms, as well as ways to prevent them in clinical practice. *Immunol Res*. Published online March 19, 2024. DOI: 10.1007/s12026-024-09473-w
60. Eberlein B, Mathes S, Darsow U, Biedermann T, Brockow K. Allergy to PEG (polyethylene glycol) - sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2. *Hum Vaccin Immunother*. 2024;20(1):2312600.
61. Perkins GB, Tunbridge MJ, Hurtado PR, Zuiani J, Mhatre S, Yip KH, et al. PEGylated liposomes for diagnosis of polyethylene glycol allergy. *J Allergy Clin Immunol*. Published online May 6, 2024. DOI: 10.1016/j.jaci.2024.03.030
62. Tuttle KL, Lynch DM, Marquis K, Besz KM, Matulonis UA, Castells MC. Phenotypes of hypersensitivity reactions to pegylated liposomal doxorubicin: Safety and efficacy of 128 rapid desensitizations. *J Allergy Clin Immunol Pract*. 2024;12(5):1348-1350.e2.
63. Wells HG. Studies on the chemistry of anaphylaxis (III). Experiments with isolated proteins, especially those of the hen's egg. *J Infect Diseases*. 1911;9:147-171.
64. Gell PGH, Harington CR, Rivers RP. The antigenic function of simple chemical compounds; production of precipitins in rabbits. *Brit J Exp Pathol*. 1946;27(5):267-286.
65. Olivier CE, Lima RPS, Pinto DG, Santos RAPG. The Plasma preincubation with papain before the assay suggests that a gell and coombs type II reaction is been demonstrated by the leukocyte adherence inhibition test. *Biomed J Sci Techn Res*. 2021;36(3):28647-28655.
66. Thomson DMP. Assessment of immune status by the leukocyte adherence inhibition test. Academic Press: New York, 1982;17,380 p.
67. Tong AW, Burger DR, Finke P, Barney C, Vandebark AA, Vetto RM. Assessment of the mechanism of the leukocyte adherence inhibition test. *Cancer Res*. 1979;39(2 Pt 2):597-603.
68. Fink A, Heller L, Eliraz A, Weisman Z, Miskin A, Schlezinger M, et al. Allergen-specific leukocyte adherence inhibition (LAI) assay: Sensitivity, specificity and mechanism. *Immunol Lett*. 1987;16(1):65-70.
69. Halliday WJ, Maluish A, Miller S. Blocking and unblocking of cell-mediated anti-tumor immunity in mice, as detected by the leucocyte adherence inhibition test. *Cell Immunol*. 1974;10(3):467-475.
70. Chung MK, House JS, Akhtari FS, Makris KC, Langston MA, Islam KT, et al. Decoding the exposome: Data science methodologies and implications in exposome-wide association studies (ExWASs). *Exposome*. 2024;4(1): osae001.
71. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPG, Lima RPS. Exploring the role of leukocyte adherence inhibition test in assessing Non-IgE mediated immunoreactivity to benzoic acid in allergic patients. *Asian J Immunol*; 2024;7(1):63-70.
72. Anouar S, Hazim R, Brahim A. Interferences in immunological assays: Causes, detection, and prevention. *Asian J Immunol*. 2024;7(1):71-78.

73. Chiarentin L, Gonçalves C, Augusto C, Miranda M, Cardoso C, Vitorino C. Drilling into “quality by design” approach for analytical methods. *Crit Rev Analytical Chem.* 2023;1-42.
74. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA.* 2013;310(20): 2191-4.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/119914>